Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Imperial Capital Hires Three Senior Investment Grade Sales Professionals Expanding its Credit Sales & Trading Business
-
Orchid Island Capital Announces March 2017 Monthly Dividend and February 28, 2017 RMBS Portfolio Characteristics
-
Health Insurance Innovations (HIIQ) Prices 3M Secondary Public Offering at $14/Share
-
Health Insurance Innovations, Inc. Announces Pricing of Secondary Public Offering by Selling Stockholders
-
Cantor Fitzgerald Remains Bullish on Cerus (CERS) Following 4Q
-
Cantor Fitzgerald Remains Sidelined on CafePress (PRSS) Following 4Q
-
Aerie Pharma (AERI) PT Raised to $56 at Cantor Fitzgerald
-
Hooper Holmes (HH) to Merge with Provant Health Solutions LLC
-
Hooper Holmes and Provant to Merge
-
Health Insurance Innovations (HIIQ) Announces Launch of Secondary Public Offering
-
Cerus Corporation Reports Fourth Quarter and Year End 2016 Results
-
Health Insurance Innovations, Inc. Announces Launch of Secondary Public Offering by Selling Stockholders
-
Supernus Pharma (SUPN): Trokendi XR Settlement Removes a Minor Overhang - Cantor
-
Supernus Pharma (SUPN): Trokendi XR Settlement Removes a Minor Overhang - Cantor
-
Chatham Lodging Trust (CLDT): Houston and Western PA Remain Soft - Cantor
-
Cantor Fitzgerald Remains Sidelined on Eastgroup Properties (EGP) After Adjusting Estimates
-
Omnicell (OMCL) PT Raised to $43 at Cantor Fitzgerald
-
Lipocine (LPCN) Enters Sales Agreement to Offer Up to $20M in Common Stock
-
Omnicell (OMCL) PT Raised to $43 at Cantor Fitzgerald Following Increased Visibility into XT Launch; 'Higher Rev Growth, Improved Margins'
-
Cantor Fitzgerald Reiterates Overweight Rating and $15 PT on NantHealth (NH); 'L-T Outlook is Attractive'
-
TherapeuticsMD (TXMD): Investor Day Recap - Cantor
-
Paratek Pharmaceuticals (PRTK): Earnings Behind Us, Look To Upcoming Readouts - Cantor
-
AMAG Pharmaceuticals (AMAG) PT Raised to $25 at Cantor Fitzgerald on Value of Intrarosa Upside;
-
Cantor Fitzgerald Remains Bullish on Five Star Quality Care (FVE) Following 4Q
-
Odebrecht bonds slump as scandal spillover fans investor skepticism
-
Prothena Corp. (PRTA) Prices 2.7M Offering at $57.50/Share
-
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
-
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
-
Cantor Fitzgerald Remains Bullish on Waters Corp. (WAT) Following Investor Day
-
Regulus Therapeutics (RGLS) PT Lowered to $4 at Cantor Fitzgerald; Expect RG-101 Decision in 4Q17
-
Cantor Fitzgerald Reiterates Overweight Rating and $175 PT on Expedia (EXPE) Following Mgmt Meetings; 'Critical Year' for HomeAway
-
Prothena Corp. (PRTA) Commences 2.7M Offering of Ordinary Shares
-
Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares
-
Prothena Announces Public Offering of Ordinary Shares
-
Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update
-
Glaukos Corporation (GKOS) PT Raised to $54 at Cantor Fitzgerald; 4Q Results, 4Q Sales Growth, '17 Guidance, All 'Impressive'
-
Cantor Fitzgerald Downgrades The Trade Desk (TTD) to Neutral
-
DepoMed Inc (DEPO) PT Lowered to $19 at Cantor Fitzgerald
-
Freddie Mac Prices $241 Million Multifamily K-Deal, K-J12
-
Cantor Fitzgerald Reiterates Outperform on Ashford Hospitality Trust (AHT) Following 4Q
-
AMAG Pharma (AMAG): Rekynda Data Could Blunt the Impact of Makena Competition - Cantor
-
Shutterstock (SSTK) PT Lowered to $43 at Cantor Fitzgerald Following 4Q Miss
-
Sabra Healthcare REIT Inc. (SBRA) PT Raised to $30 at Cantor Fitzgerald on 4Q FFO Beat; 'Re-Focused on Growth'
-
CardConnect Corp. (CCN) PT Raised to $17 at Cantor Fitzgerald on 'High Annual Revenue Visibility'
-
Cantor Fitzgerald Maintains Neutral Rating and $2 PT on Novavax (NOVA) Following Mixed Q4 Results
-
The Priceline Group (PCLN) PT Raised to $1,850 at Cantor Fitzgerald
-
Shutterstock (SSTK) PT Lowered to $43 at Cantor Fitzgerald
-
Intrepid Potash Announces Fourth Quarter and Full Year 2016 Results
-
Facebook's virtual reality ambitions could be threatened by court order
-
Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

